CMA finds Actavis UK charged “excessive and unfair” prices

Drugmaker Actavis overcharged the UK’S national health service for hydrocortisone, a drug used to treat life-threatening conditions including Addison’s disease, the Competition and Markets Authority provisionally found today.


Get unlimited access to all Global Competition Review content